TRAVERSE followed more than 5,200 men who already had heart disease or a high risk of it, for about three years. No increase in heart attacks, strokes or cardiac deaths. No increase in prostate cancer.
That is the headline. The rest of this page is the fine print, and the fine print is the reason to believe the headline.
Someone told you it wrecks your heart. Someone else told you it causes prostate cancer. Both claims arrive with total confidence, usually from people who have never read the trial.
Where the fear actually came from
For years testosterone therapy carried a warning about heart attacks and strokes. That warning did not come from a large trial. It came from a couple of older, weaker studies, and it was enough to make a generation of men, and their doctors, nervous.
Weak evidence is still evidence, and the honest response to it is not to wave it away. It is to test the question properly. That is what happened.
The trial built to settle it
TRAVERSE followed more than 5,200 men for about three years. It is the largest trial built to test testosterone's safety for the heart, and it exists because regulators wanted the question answered rather than argued about.
The design is the part worth understanding. These were not healthy young men in a gym. They were older men who already had heart disease or a high risk of it. If testosterone caused heart problems, this is the group in which it would show up first and most clearly. Stacking the deck against the treatment is exactly what makes the result worth reading.
The heart result
No increase in heart attacks, strokes or heart related deaths compared with placebo. Men on testosterone carried essentially the same cardiovascular risk as men on the dummy treatment. That was the question regulators had been waiting on, and it was answered directly.
The prostate result
No increase in prostate cancer or prostate related problems. The rates were low and similar to the placebo group. Urinary symptoms did not get worse.
Now the part that gets left out
Alongside those results, the trial recorded slightly higher rates of a few specific events in the testosterone group:
- Atrial fibrillation, an irregular heartbeat.
- Short term kidney injury.
- Pulmonary embolism, clots in the lungs.
- A small rise in fractures, reported in a separate analysis.
These are not the heart attacks the old headlines warned about. That question was answered, and the answer was no. But they are not nothing either. The trial was not built to explain these smaller signals, and the researchers did not pin them on a single cause. So the accurate description is a signal to watch rather than proven organ damage, and anyone telling you either that this is evidence of harm or that it can be safely ignored has gone past what the data supports.
What three years cannot tell you. About three years of follow up is a serious answer to a serious question. It is not a lifetime. The findings describe men with a confirmed diagnosis, treated to normal levels and monitored throughout. They do not describe every man, every dose, or every duration.
The reassurance that comes with an asterisk
Testosterone raises red blood cell production. In this trial, modest rises in hematocrit, the marker for how thick the blood is, were not linked to more clotting events. That is genuinely reassuring, and it is also narrower than it sounds. The wider evidence on large rises is still debated. The word modest is doing real work in that sentence.
The trials also documented benefits that were not the point of the study. Testosterone corrected anemia, a low red blood cell count, in many men. Desire and sexual activity improved.
The numbers that get watched
Published practice here is specific rather than vague. Before anything starts, baseline blood work includes hematocrit, and PSA, the prostate marker, in men 40 and over. Treatment is held off when hematocrit already sits above 48%, and in the presence of a recent heart attack or stroke, untreated severe sleep apnea, or an active prostate or breast cancer.
The safety TRAVERSE found applied to men who had been correctly diagnosed and who were under medical supervision for the whole run. That condition is part of the evidence, not a footnote.
So, is it safe
For the population studied, the honest summary reads like this. The two fears that bring most men to a page like this were tested in the group most likely to expose them, and neither was confirmed. Smaller signals did appear and remain unexplained. Safety was established for men who were properly diagnosed, treated to a normal range and monitored on a schedule, and that final clause is not decoration. It is the condition the evidence came with.
This site prescribes nothing and sells nothing. What it can do is tell you what the trial found and what the trial did not settle, which is more than most pages on this subject manage.
The next question, who is actually qualified to read your numbers against your symptoms, is covered in who should assess you. The timeline of what changes and when is in how long it takes.